Kura Oncology (KURA) Misses Q2 EPS by 34c

Kura Oncology (NASDAQ: KURA) reported Q2 EPS of ($0.75), $0.34 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $15.3 million versus the consensus estimate of $39.11 million.

For earnings history and earnings-related data on Kura Oncology (KURA) click here.

You May Also Be Interested In

• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform
• Jefferies Starts Trastor Real Estate Investment Co (TRASTOR:GA) at Buy
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings